We are committed to finding a cure for WM.

Waldenström macroglobulinemia

2019 WMFC Educational Forum Presentation – Dr. Chen

Dr. Christine Chen from the Princess Margaret Cancer Centre presenting on ” Navigating Treatment Options for Waldenstrom’s Macroglobulinemia in Canada” at the 2019 WMFC Educational Forum Toronto – April 2019

2019 WMFC Educational Forum Presentation – Dr. Carrasco

Dr. Ruben Carrasco from the Department of Pathology, BWH and Department of Oncologic Pathology, DFCI presenting: Engineering a mouse model of Lymphoplasmacytic Lymphoma/Waldenstroms Macroglobulinemia (LPL/WM) at the 2019 WMFC Educational Forum Toronto – April 2019

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Source: https://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-zanubrutinib-new-trial-treatment/article/801383/

A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading